Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pasquale Rescigno

Showing results (1-10 of 154) with videos related to

Pageof 16
Sort By:
Cancer Treatment and Research Communications|December 11, 2025
Illuminating the spectrum of genomic sequencing approaches in the precision oncology era: A UK perspectivePasquale Rescigno, Alastair Greystoke
Future Oncology (London, England)|February 25, 2014
The potential detrimental effect of corticosteroids in prostate cancerPasquale Rescigno, Giuseppe di Lorenzo
Nature Reviews. Urology|November 24, 2018
Immunotherapy for lethal prostate cancerPasquale Rescigno, Johann S de Bono
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Platinum drug sensitivity and resistance in testicular germ cell tumors: two sides of the same coinPasquale Rescigno, Margaret Ottaviano, Giovannella Palmieri
Minerva Urology and Nephrology|December 21, 2023
Genomic tests for persistence PSA after radical prostatectomy: smoke and mirrors or new effective tools for the clinical decision-making?Enrico Checcucci, Christoph Oing, Pasquale Rescigno
European Urology|June 1, 2016
Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31Pasquale Rescigno, Johann S de Bono
Asian Journal of Urology|August 29, 2022
Gene expression profiles and treatments for metastatic renal cell carcinoma: What does still need to be defined?Emilio F Giunta, Pasquale Rescigno, Roberto Pili
Current Opinion in Supportive and Palliative Care|July 7, 2018
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancerPasquale Rescigno, Robert Chandler, Johann de Bono
JAMA Oncology|January 1, 2016
Chemical or Surgical Castration--Is This Still an Important Question?Michael Kolinsky, Pasquale Rescigno, Johann S de Bono
Minerva Urology and Nephrology|May 26, 2021
The emerging role of whole-body magnetic resonance imaging in advanced prostate cancerAndra Curcean, Filippo Russo, Pasquale Rescigno, et al.
Pageof 16

Showing results (1-10 of 154) with videos related to

Sort By:
Pageof 16
Cancer Treatment and Research Communications|December 11, 2025
Illuminating the spectrum of genomic sequencing approaches in the precision oncology era: A UK perspectivePasquale Rescigno, Alastair Greystoke
Future Oncology (London, England)|February 25, 2014
The potential detrimental effect of corticosteroids in prostate cancerPasquale Rescigno, Giuseppe di Lorenzo
Nature Reviews. Urology|November 24, 2018
Immunotherapy for lethal prostate cancerPasquale Rescigno, Johann S de Bono
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Platinum drug sensitivity and resistance in testicular germ cell tumors: two sides of the same coinPasquale Rescigno, Margaret Ottaviano, Giovannella Palmieri
Minerva Urology and Nephrology|December 21, 2023
Genomic tests for persistence PSA after radical prostatectomy: smoke and mirrors or new effective tools for the clinical decision-making?Enrico Checcucci, Christoph Oing, Pasquale Rescigno
European Urology|June 1, 2016
Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31Pasquale Rescigno, Johann S de Bono
Asian Journal of Urology|August 29, 2022
Gene expression profiles and treatments for metastatic renal cell carcinoma: What does still need to be defined?Emilio F Giunta, Pasquale Rescigno, Roberto Pili
Current Opinion in Supportive and Palliative Care|July 7, 2018
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancerPasquale Rescigno, Robert Chandler, Johann de Bono
JAMA Oncology|January 1, 2016
Chemical or Surgical Castration--Is This Still an Important Question?Michael Kolinsky, Pasquale Rescigno, Johann S de Bono
Minerva Urology and Nephrology|May 26, 2021
The emerging role of whole-body magnetic resonance imaging in advanced prostate cancerAndra Curcean, Filippo Russo, Pasquale Rescigno, et al.
Pageof 16